Arterial hypertension - clinical trials update 2022.

Abstract

Hypertension is the most prevalent cardiovascular risk factor worldwide and is associated with increased cardiovascular morbidity and mortality. Despite the availability of multimodal therapeutic approaches, a large number of patients do not achieve guideline-recommended blood pressure targets, which reiterates the importance of continued research in the field. This article summarizes and discusses the most relevant clinical trials in hypertension research published in 2021 and 2022. The topics include new insights into treatment targets in the elderly, novel findings of salt consumption and lifestyle interventions in resistant hypertension, new evidence about early antihypertensive combination therapy and the use of angiotensin II receptor blocker neprilysin inhibitors in resistant hypertension, as well as data regarding the safety of antihypertensive drugs with respect to cancerogeneity and regarding the impact of acetaminophen, a commonly used pain medication, on blood pressure. Finally, we provide an update on recent evidence on renal denervation and its role in current hypertension management.

• Authors: Felix Götzinger, Michael Kunz, Lucas Lauder, Michael Böhm, Felix Mahfoud
• Journal: Hypertension research : official journal of the Japanese Society of Hypertension (Hypertens Res) Vol. 45 Issue 7 Pg. 1140-1146 (07 2022) ISSN: 1348-4214 [Electronic] England
• PMID: 35562419 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.

Chemical References

• Antihypertensive Agents

Topics

• Aged
• Antihypertensive Agents (therapeutic use)
• Blood Pressure
• Humans
• Hypertension (drug therapy)
• Kidney
• Life Style